Alibaba lost 9.3 billion and sold 100% of its shares in Intime, while Youngor Group made another successful investment.

① Alibaba will sell 100% equity of Intime Department Store to a buyer consortium composed of Youngor Group and Intime management team members. ② This year, Youngor Group has strengthened its investment in physical businesses, opening 13 new fashion experience stores offline. ③ Alibaba entered Intime in 2014 and gradually became the largest shareholder; as New Retail progressed to a decline, Alibaba ultimately let go of Intime.

cls.cnDec 17 01:40 ET

7.4 billion! Alibaba "shakes off" the burden, Youngor Group officially takes over Silver Intime Department Store.

① Analysts have pointed out that although Youngor Group's acquisition helps its expansion in the Retail Trade market, the department store industry is in a state of continuous contraction. ② Alibaba's acquisitions of Intime and RT-Mart and other physical retail companies aimed to promote brand presence on Tmall, accelerate the digital transformation of the Retail Trade, and explore the application of instant retail innovation models in physical retail.

cls.cnDec 16 23:53 ET

Jiangsu Skyray Instrument has been designated as a special treat and fined 3 million yuan. In recent years, there have been 10 other instances of illegal operation in production and management. | Quick read of the announcement.

① Jiangsu Skyray Instrument was fined 3 million yuan by the Securities Regulatory Commission, and several executives including chairman Liu Zhaogui were also penalized; ② The company's stocks will be subject to other risk warnings by the Shenzhen Stock Exchange, changed to "ST Jiangsu Skyray"; ③ In recent years, the company has faced up to 10 cases of violations related to environmental protection, safety regulations, and other operational misconduct.

cls.cnDec 8 07:46 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

China Chengtong accelerates the integration of its papermaking business. Yueyang Forest & Paper plans to "recover" old assets for 1.28 billion.

① China Chengtong integrates the papermaking business, mcc meili cloud computing industry investment and yueyang forest & paper are both taking action; ② yueyang forest & paper plans to acquire a pulp company that was divested years ago for 1.28 billion cash; ③ the symbol has had stable profits in the past two years, while yueyang forest & paper's operation continues to be under pressure; ④ the symbol was divested by yueyang forest & paper in 2015 due to poor performance.

cls.cnNov 26 08:35 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22 11:06 ET